Clinical Intergroup
Phase I-II-Project
Multiply
Registry
Pathology Panel
News & Dates
Kami J.Maddocks

M.D. Kami J. Maddocks

The Ohio State University

Department of Internal Medicine, Division of Hematology
 
2121 Kenny Road 7th Floor, Office
7270 Columbus, Ohio
 
+1 614 293 1395
 

Literature

Publication Summary:

I have included my CV which has ~140 lymphoma/CLL related publications including ~40 publications related to MCL.  MCL related publications include results of clinical trials with targeted and novel therapies including BRI, Palbo-Ibrutinib, R-Ven-Acal, R2-Acala, R-VenLen, pirtobrutinib, and numerous phase 1 studies with targeted therapies in B cell malignancies including MCL; post-ibrutinib outcomes in MCL; real world outcomes evidence including with transplantation, high-risk disease, POD24, treatment patterns and outcomes.  Publications also include mechanisms of resistance to BTKi/ibrutinib for B-cell malignancies.  Additional publications not highlighted but in CV (~100) include further BTKi resistance in CLL; CLL clinical trials largely with BTKi based approaches; clinical trials of novel therapies in DLBCL (tafa/len for one) and FL and outcomes in numerous b-cell malignancies including DLBCL with high-risk features.

 

MCL Related Publications:

  1. Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood. 2015 Jan 8;125(2):242-8. doi: 10.1182/blood-2014 08-597914.Epub 2014 Oct 29. PMID: 25355819     
  2. Maddocks K, Blum KA. Treatment strategies in mantle cell lymphoma. Cancer Treat Res. 2015;165:251 70. doi: 10.1007/978-3-319-13150-4_10. PMID: 2565561
  3. Maddocks K, Blum KA. Ibrutinib in B-cell Lymphomas. Current Treat Options Oncol. 2014 June;15(2):226-37. PMID: 24481980.
  4. Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA. The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Br J Haematol. 2015 Jun;169(5):701-10. doi: 10.1111/bjh.13354. Epub 2015 Apr 7. PMC7297055.     
  5. Martin P, Maddocks K, Leonard JP, Ruan J, Goy A, Wagner-Johnston N, Rule S, Advani R, Iberri D, Phillips T, Spurgeon S, Kozin E, Noto K, Chen Z, Jurczak W, Auer R, Chmielowska E, Stilgenbauer S, Bloehdorn J, Portell C, Williams ME, Dreyling M, Barr PM, Chen-Kiang S, DiLiberto M, Furman RR, Blum KA. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016 Mar 24;127(12):1559-63. doi: 10.1182/blood-2015-10-673145. PMID 26764355        
  6. Cohen JB, Maddocks KJ, Huang Y, Christian BA, Jaglowski SM, Flowers CR, Blum KA. A phase 2 trial of alistertib in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Leuk Lymphoma. 2017 Sep;58(9):1-2. doi: 10.1080/10428194.2017.1289527. PMID 28278718.
  7. Jurczak W, Zinzani PL, Gaidano G, Goy A, Provencio M, Nagy Z, Robak T, Maddocks K, Buske C, Ambarkhane S, Winderlich M, Dirnberger-Hertweck M, Korolkiewicz R, Blum KA. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Ann Oncol. 2018 May 1;29(5):1266-1272. doi: 10.1093/annonc/mdy056. PMC5961010.
  8. Maddocks K. Update on Mantle Cell Lymphoma. Blood. 2018 Oct 18; 132(16):1647-1656. doi: 10.1182/blood-2018-03-791392. Epub 2018 Aug 28. Review. PMID: 30154113
  9. Stathis A, Flinn IW, Madan S, Maddocks K, Freedman A, Weitman S, Zucca E, Munteanu MC, Lia Palomba M. Safety, tolerability, and preliminary activity of IMGN529, a CD37-targeted antibody-drug conjugate, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: a dose-escalation, phase I study. Invest New Drugs. 2018 Oct;36(5):869-876. doi: 10.1007/s10637-018-0570-4. Epub 2018 Feb 17. PMC6153548.
  10. Maddocks K. Chemotherapy-free induction in MCL: ready for prime time? Blood. 2018 Nov 8;132(19):2001-2002. doi: 10.1182/blood-2018-09-875203. PMID: 30409891
  11. Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling L, Dittus C, Chen Z, Huang X, Inghirami G, DiLiberto M, Chen-Kiang S, Leonard JP. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019 Mar 14;133(11):1201-1204. doi: 10.1182/blood-2018-11-886457. Epub 2019 Jan 28. Erratum in: Blood. 2019 Sep 12;134(11):908. doi: 10.1182/blood.2019002741. PMC6418474.
  12. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. J Clin Oncol. 2019 Feb 20;37(6):471-480. doi: 10.1200/JCO.18.00690. Epub 2019 Jan 7. PMC7554677.
  13. Bond DA, Alinari L, Maddocks K. Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions. Clin Adv Hematol Oncol. 2019 Apr;17(4):223-233. PMID: 31188814.
  14. Ayyappan S, Maddocks K. Novel and emerging therapies for B cell lymphoma. J Hematol Oncol. 2019 Jul 25;12(1):82. doi: 10.1186/s13045-019-0752-3. Review. PMID: 31345247
  15. Harrington BK, Wheeler E, Hornbuckle K, Y Shana'ah A, Youssef Y, Smith L, Hassan Ii Q, Klamer B, Zhang X, Long M, Baiocchi RA, Maddocks K, Johnson AJ, Byrd JC, Alinari L. Modulation of immune checkpoint molecule expression in mantle cell lymphoma. Leuk Lymphoma. 2019 Oct;60(10):2498-2507. doi: 10.1080/10428194.2019.1569231. Epub 2019 Mar 1. PMC6773518.
  16. Bond DA, Maddocks KJ. Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma. Hematol Oncol Clin North Am. 2020 Oct;34(5):903-921. doi: 10.1016/j.hoc.2020.06.007. Epub 2020 Aug 1. PMID: 32861286 Review.
  17. Maddocks K. Building on BTK inhibition in MCL. Blood. 2021 Feb 18;137(7):861-862. doi: 10.1182/blood.2020009781.PMID: 33599764
  18. Bond DA, Martin P, Maddocks KJ. Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions. J Clin Med. 2021 Mar 14;10(6):1207. doi: 10.3390/jcm10061207. PMID: 33799484
  19. Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant. 2021 Sep;27(9):720-728. doi: 10.1016/j.jtct.2021.03.001. PMC8447221.
  20. Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS. American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. Transplant Cell Ther. 2021 Sep;27(9):720-728. doi: 10.1016/j.jtct.2021.03.001. PMID: 34452722.
  21. Karmali R, Switchenko JM, Goyal S, Shanmugasundaram K, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, Fenske TS, Hamadani M, Guo J, Malecek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. Am J Hematol. 2021 Nov 1;96(11):1374-1384. doi: 10.1002/ajh.26306. Epub 2021 Aug 10. PMC8511300.
  22. Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, Fenske TS, Malecek MK, Kahl BS, Flowers CR, Blum KA, Cohen JB. Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. Blood Adv. 202114;5(23):5179-5189. doi: 10.1182/bloodadvances.2021004765. PMID: 34516611.
  23. Sawalha Y, Maddocks K. Novel treatments in B cell non-Hodgkin's lymphomas. BMJ. 2022 Apr 20;377:e063439. PMID: 35443983.
  24. Bond DA, Huang Y, Christian BA, Jaglowski S, Benson D, Alinari L, Baiocchi RA, Cohen JB, Blum KA, Maddocks KJ. A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. Leuk Lymphoma. 2022 Jul;63(7):1750-1753. doi: 10.1080/10428194.2022.2034154. Epub 2022 Feb 6. PMID: 35129029.
  25. Hanel W, Lata P, Youssef Y, Tran H, Tsyba L, Sehgal L, Blaser BW, Huszar D, Helmig-Mason J, Zhang L, Schrock MS, Summers MK, Chan WK, Prouty A, Mundy-Bosse BL, Chen-Kiang S, Danilov AV, Maddocks K, Baiocchi RA, Alinari L. A sumoylation program is essential for Maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells. Exp Hematol Oncol. 2022 Jul 13;11(1):40. PMC9277803.
  26. Maddocks K. EXABS-225-NQ Next Questions: Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S113-S114. doi: 10.1016/S2152-2650(22)00688-7. PMID: 36163710.
  27. Martin P, Cohen JB, Wang M, Kumar A, Hill B, Villa D, Switchenko JM, Kahl B, Maddocks K, Grover NS, Qi K, Parisi L, Daly K, Zhu A, Salles G. Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. J Clin Oncol. 2023 Jan 20;41(3):541-554. doi: 10.1200/JCO.21.02698. Epub 2022 Jun 28. PMC9870229.
  28. Epperla N, Switchenko JM, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews SP, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, Fenske TS, Martin P, Guo J, Malecek MK, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman A, Hsi ED, Maddocks K, Blum K, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 2023 Jun 13;7(11):2287-2296. PMC10225877.
  29. Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023 Aug 20;41(24):3988-3997. doi: 10.1200/JCO.23.00562. Epub 2023 May 16. PMC10461952.
  30. Phillips TJ, Bond DA, Takiar R, Kump KJ, Kandarpa M, Boonstra P, Mayer TL, Nachar VR, Wilcox RA, Carty SA, Karimi YH, Nikolovska-Coleska Z, Kaminski MS, Herrera AF, Maddocks K, Popplewell L, Danilov AV. Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. Blood Adv. 2023 Aug 22;7(16):4518-4527. PMC10425679.
  31. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang ML, Cohen J, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari SK, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond DA, Bachanova V, Kolla B, Chavez JC, Shah BD, Lansigan F, Burns TF, Donovan A, Wagner-Johnston ND, Messmer MR, Mehta A, Anderson J, Reddy N, Kovach A, Landsburg DJ, Glenn MJ, Inwards DJ, Ristow K, Karmali R, Kaplan J, Caimi PF, Rajguru SA, Evens AM, Klein AK, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Outcomes of Patients with Blastoid and Pleomorphic Variant Mantle Cell Lymphoma. Blood Adv. 2023 Dec 26;7(24):7393-7401. PMC10758713.
  32. Martin P, Maddocks K. Does TRIANGLE take down transplantation in mantle cell lymphoma? Lancet. 2024 May 25;403(10441):2264-2265. doi: 10.1016/S0140-6736(24)00301-5. Epub 2024 May 2. PMID: 38705162.
  33. Maddocks K. BTKi is better: a lesson learned? Blood. 2024 Aug 29;144(9):926-927. PMID: 39207807.
  34. Wang M, Robak T, Maddocks KJ, Phillips T, Smith SD, Gallinson D, Calvo R, Wun CC, Munugalavadla V, Jurczak W. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis. Blood Adv. 2024 Sep 10;8(17):4539-4548. doi: 10.1182/bloodadvances.2023012424. PMC11399641.
  35. Sawalha Y, Maddocks K. Your chemo is no good here: management of high-risk MCL. Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):34-41. PMID: 39644043.
  36. Roeker LE, Coombs CC, Shah NN, Jurczak W, Woyach JA, Cheah CY, Patel K, Maddocks K, Wang Y, Zinzani PL, Munir T, Koh Y, Thompson MC, Muehlenbein CE, Wang C, Sizelove R, Abhyankar S, Hasanabba S, Tsai DE, Eyre TA, Wang M. Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol. 2025;148(2):180-197. doi: 10.1159/000539587. Epub 2024 Jun 5. PMC11617602.
  37. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y,Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013 Oct 10; 122(15): 2539-49. PMID: 23886836.
  38. Mahoney E, Maddocks K, Flynn J, Jones J, Cole SL, Zhang X, Byrd JC, Johnson AJ. Identification Of Endoplasmic Reticulum Stress Inducing Agents By Antagonizing Autophagy: A New Potential Strategy for Identification Of Anti-Cancer Therapeutics In B-Cell Malignancies. Leuk Lymphoma. 2013 Dec; 54(12):2685-92. PMID: 23469959.
  39. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, Lucas D, Williams K, Zhao W, Rassenti L, Ghia E, Kipps TJ, Mantel R, Jones J, Flynn J, Maddocks K, O'Brien S, Furman RR, James DF, Clow F, Lozanski G, Johnson AJ, Byrd JC. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014 Mar 20; 123(12): 1810-7. PMID: 24415539.
  40. Guinn D, Ruppert AS, Maddocks K, Jaglowski S, Gordon A, Lin TS, Larson R, Marcucci G, Hertlein E, Woyach J, Johnson AJ, Byrd JC. miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. Leukemia. 2015 May;29(5):1210-3. doi: 10.1038/leu.2014.344. Epub 2014 Dec 9. PMID: 254868872
  41. Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, Andritsos LA, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017 Sep 8;1(20):1739-1748. doi: 10.1182/bloodadvances.2017009720. PMC5728342.